Paper Details

  1. Home
  2. Paper Details

Combination of ultra-low-dose isotretinoin and antihistamines in treating Morbihan disease - a new long-term approach with excellent results and a minimum of side effects.

Author: SchallerMartin, WelschKatharina

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

A combination of ultra-low-dose isotretinoin and antihistamines effectively reduced erythema and edema in Morbihan disease patients, with minimal side effects.
Paper Details　
Original Abstract of the Article :
Morbihan disease is characterized by erythema and solid edema in the two upper thirds of the face. Underlying factors are an imbalance in lymphatic drainage, chronic inflammation, and mast cells leading to fibrosis. Treatment options known thus far have led to unsatisfactory results and have often b...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/09546634.2020.1721417

データ提供：米国国立医学図書館（NLM）

A New Approach to Morbihan Disease: Combining Ultra-Low-Dose Isotretinoin and Antihistamines

This research delves into the realm of dermatology, specifically addressing the challenges of Morbihan disease. The study explores a novel long-term treatment strategy using a combination of ultra-low-dose isotretinoin and antihistamines. This approach was tested on four patients over an average of 14 months. The researchers used photodocumentation and measurements to analyze the effectiveness of this treatment. The findings indicate a significant reduction in erythema (91.5%) and edema (85%) in all patients. This study suggests a potential shift in therapeutic approaches for Morbihan disease, highlighting the effectiveness and low risk of side effects associated with this combination therapy.

A Promising Solution for a Challenging Skin Condition

The results of this study are quite encouraging. With a significant reduction in both erythema and edema, this combination therapy shows promise as a viable treatment option for Morbihan disease. Imagine a desert oasis, providing relief from the harsh conditions, much like this therapy offers a respite from the discomfort of Morbihan disease.

A Step Towards Better Skin Health

The study's findings suggest that this new approach could be a valuable tool in managing Morbihan disease. This approach could provide relief from the discomfort associated with the condition, potentially enhancing quality of life for those affected. It's like a gentle desert breeze, offering a refreshing change from the heat and dryness of the disease.

Dr.Camel's Conclusion

The study highlights the potential benefits of combining ultra-low-dose isotretinoin and antihistamines in treating Morbihan disease. This novel approach offers a promising alternative for patients struggling with this challenging skin condition. While more research is needed, the study's findings provide a beacon of hope for a less invasive and more effective treatment option.
Date :
  1. Date Completed 2021-11-29
  2. Date Revised 2021-11-29
Further Info :

Pubmed ID

32022617

DOI: Digital Object Identifier

10.1080/09546634.2020.1721417

Related Literature

Article Analysis
・Side Effects of isotretinoin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.